Form 4: Rigel CFO Schorno Vests Performance Stock Options

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, has vested 7,394 performance-based stock options after a key metric was met on September 15, 2025.

Summary

• Dean L. Schorno, Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals Inc. (RIGL), reported the vesting of performance-based stock options.
• The options, granted on January 29, 2025, cover 7,394 shares of the Issuer's common stock.
• The exercise price for these options is $22.49 per share, which was the closing price of the Issuer's common stock on Nasdaq on the date of grant.
• A performance metric associated with the grant was satisfied on September 15, 2025, leading to the full vesting of the options on that date.

Sentiment

Score: 7

Explanation: The vesting of performance-based options for a key executive is generally positive, indicating the achievement of internal company goals and aligning executive incentives with shareholder interests. It's a routine compensation event but reflects positively on goal attainment.

Positives

• EVP & CFO Dean L. Schorno's performance-based stock options for 7,394 shares have fully vested, indicating the achievement of a company performance metric.
• The vesting aligns executive compensation with company performance, potentially motivating continued strong leadership and strategic execution.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the expiration date of the stock option.

Industry Context

Performance-based stock options are a common executive compensation tool in the biotechnology and pharmaceutical industries, designed to align management incentives with long-term shareholder value creation and the achievement of strategic milestones, such as clinical trial progress or regulatory approvals.

Stakeholder Impact

• **Shareholders:** The vesting of performance-based options for a key executive aligns management's interests with shareholder value creation, as the options' value is tied to the company's stock performance.
• **Employees:** May signal a positive internal environment where performance goals are being met, potentially boosting morale and reinforcing a performance-driven culture.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event where performance-based stock options have vested. While positive as it indicates the achievement of internal company metrics and aligns executive incentives, it does not provide new fundamental information about the company's financial health or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals.

Keywords

Rigel Pharmaceuticals, RIGL, Dean L. Schorno, Stock Option, Performance-Based, Executive Compensation, SEC Form 4, Insider Transaction